ASLAN Pharmaceuticals to Participate in Fireside Chat at Jefferies Global Healthcare Conference

MENLO PARK, Calif. and SINGAPORE, May 31, 2022 (GLOBE NEWSWIRE) — ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that Dr Carl Firth, CEO, will participate in a fireside chat at the Jefferies Global Healthcare Conference. The conference will be held in-person in New York, NY, June 8 – 10, 2022.

Management will be available for virtual one-on-one meetings throughout the conference.


Fireside Chat details


Date:

Wednesday, June 8, 2022


Time:

10:00am ET


Track

: 9


Webcast link:

Click

here

to listen in live or via replay

A replay of the presentation will be available for 90 days at the link above and in the News & Events section of ASLAN Pharmaceutical’s Investor Relations

website

.



Media and IR contacts


Emma Thompson


Spurwing Communications

Tel: +65 6206 7350

Email:

[email protected]


Ashley R. Robinson


LifeSci Advisors, LLC

Tel: +1 (617) 430-7577

Email:

[email protected]


About ASLAN Pharmaceuticals


ASLAN Pharmaceuticals (Nasdaq:ASLN) is a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. ASLAN is currently evaluating

eblasakimab

, a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and

farudodstat

(also known as ASLAN003), a potent oral inhibitor of the enzyme, DHODH, in autoimmune disease. ASLAN has a team in Menlo Park, California, and in Singapore. For additional information please visit


www.aslanpharma.com


or follow ASLAN on

LinkedIn

.


Primary Logo